Tumor Response to ZD6126 Assessed by MRI
Author Information
Author(s): Robinson S P, McIntyre D J O, Checkley D, Tessier J J, Howe F A, Griffiths J R, Ashton S E, Ryan A J, Blakey D C, Waterton J C
Primary Institution: Cancer Research UK Biomedical Magnetic Resonance Research Group, St George's Hospital Medical School
Hypothesis
Can ZD6126 effectively target tumor blood vessels and induce necrosis in tumors?
Conclusion
ZD6126 significantly reduces tumor perfusion and induces necrosis in a dose-dependent manner.
Supporting Evidence
- ZD6126 caused massive central tumor necrosis in a dose-dependent manner.
- The highest dose of ZD6126 eliminated contrast uptake in the center of the tumor.
- 14 of the 15 tumors treated with ZD6126 showed a reduction in the highly enhancing fraction.
- Histological analysis confirmed increased necrosis with higher doses of ZD6126.
- Dynamic contrast-enhanced MRI provided a reliable measure of tumor response to ZD6126.
Takeaway
ZD6126 is a medicine that helps to kill cancer cells by blocking their blood supply, and it works better at higher doses.
Methodology
The study used dynamic contrast-enhanced MRI and multi-gradient recalled echo MRI to assess the effects of ZD6126 on tumor perfusion in rodent models.
Limitations
The study was conducted in rodent models, which may not fully replicate human responses.
Participant Demographics
Female Wistar Furth rats and C3H mice were used in the study.
Statistical Information
P-Value
p<0.02
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website